



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE RECEIVED

| In re Application of     |                              | ) |                      | AUG 2 0 2001          |
|--------------------------|------------------------------|---|----------------------|-----------------------|
| Kelsall et al.           |                              | ) |                      | TECH CENTER 1600/2900 |
|                          |                              | ) | Group Art Unit: 1644 |                       |
| Serial No. 09/196,867    |                              | ) |                      |                       |
|                          |                              | ) | Examiner: DeCloux, A | •                     |
| Filed: November 20, 1998 |                              | ) |                      |                       |
|                          | <b>3.</b>                    | ) |                      |                       |
| For:                     | METHODS OF USING CR3 AND CR4 | ) |                      |                       |
|                          | LIGANDS FOR INHIBITING       | ) |                      |                       |
|                          | INTERLEUKIN-12 TO TREAT      | ) |                      |                       |
|                          | AUTOIMMUNE DISEASE           | ) |                      |                       |
|                          |                              |   |                      |                       |
|                          |                              |   |                      |                       |

## **AMENDMENT**

Assistant Commissioner for

**Patents** 

Washington, D.C. 20231

NEEDLE & ROSENBERG, P.C.

**Suite 1200** 

The Candler Building 127 Peachtree Street, N.E. Atlanta, Georgia 30303-1811

August 7, 2001

Sir:

This is responsive to the March 7, 2001 Office Action. A Request for Extension of Time is included herewith. Please amend the application as follows.

## IN THE CLAIMS

Please amend the claims as follows. A marked up version of these claim amendments is attached hereto.